Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 7/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | ACP1 | P24666 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.40 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.40 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4511284 | 1.00 | CHEK2 (0.45) | CHEK2CHEK1LMNASMN1; SMN2MEN1 | |
| SCHEMBL4511294 | 1.00 | CHEK2 (0.45) | CHEK2CHEK1LMNASMN1; SMN2MEN1 | |
| SCHEMBL4514821 | 0.92 | MAPT (0.49) | CHEK2CHEK1LMNASMN1; SMN2MEN1 | |
| SCHEMBL4514828 | 0.92 | MAPT (0.49) | CHEK2CHEK1LMNASMN1; SMN2MEN1 | |
| SCHEMBL4514830 | 0.92 | MAPT (0.49) | CHEK2CHEK1LMNASMN1; SMN2MEN1 | |
| SCHEMBL4511784 | 0.92 | MEN1 (0.46) | CHEK2CHEK1LMNAMEN1KMT2A | |
| SCHEMBL4511790 | 0.92 | MEN1 (0.46) | CHEK2CHEK1LMNAMEN1KMT2A | |
| SCHEMBL4511786 | 0.92 | MEN1 (0.46) | CHEK2CHEK1LMNAMEN1KMT2A | |
| SCHEMBL4521146 | 0.91 | CHEK2 (0.52) | CHEK2CHEK1LMNASMN1; SMN2MEN1 | |
| SCHEMBL4521149 | 0.91 | CHEK2 (0.52) | CHEK2CHEK1LMNASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | PKD2, PKD1, AADAT | CHEK2 606/4885CHEK1 1030/4885LMNA 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.